Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01795547 · ClinicalTrials.gov registry record · Phase 3
Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 295
- Enrollment target
NCT01795547 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 295 participants.
The verdict
NCT01795547, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 295 participants
- Enrollment target
Study Summary
To assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of patients with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR®), in a naturalistic care setting by comparing it to an existing long-acting antipsychotic, paliperidone palmitate.
Interventions
- DRUG Aripiprazole and aripiprazole once-monthly
- DRUG Paliperidone and paliperidone palmitate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 295 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01795547
The ClinicalTrials.gov registry entry for NCT01795547 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 295 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Aripiprazole and aripiprazole once-monthly is the first listed.
NCT01795547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01795547 about?
NCT01795547 is a clinical study titled "Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia". To assess the effectiveness of aripiprazole once-monthly in the maintenance treatment of patients with a diagnosis of schizophrenia as defined by the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, Text Revision (DSM-IV-TR®), in a naturalistic care setting by comparing it to an e...
What is the current status of trial NCT01795547?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 295 participants. The study started on 2013-02. Estimated completion is 2014-09.
What interventions are being tested in trial NCT01795547?
The interventions under investigation include: Aripiprazole and aripiprazole once-monthly (DRUG), Paliperidone and paliperidone palmitate (DRUG).
Who is sponsoring clinical trial NCT01795547?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.